CCCC · C4 Therapeutics, Inc. · Documents

Oct 11

Current report 8-K

Director or officer change, or executive pay

Sep 3

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Aug 1

Current report 8-K

Financial results

Aug 1

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $12.01M ▲ 350.7% Net loss $17.72M Diluted EPS -$0.26

Jun 21

Current report 8-K

Shareholder vote results

Jun 10

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

May 8

Current report 8-K

Financial results

May 8

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $3.04M ▼ 19.2% Net loss $28.36M Diluted EPS -$0.41

Apr 30

Annual report to holders ARS

Annual report to holders

Apr 29

Proxy statement DEF 14A

Proxy statement

Apr 29

Proxy statement DEFA14A

Proxy statement

Mar 8

Current report 8-K

Director or officer change, or executive pay

Mar 4

Current report 8-K

Entered into a material agreement, Regulation FD disclosure

Feb 22

Current report 8-K

Financial results

Feb 22

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $20.76M ▼ 33.3% Net loss $132.49M Diluted EPS -$2.67

Jan 11

Current report 8-K

Regulation FD disclosure

Jan 9

Current report 8-K

Exit or restructuring costs, Regulation FD disclosure

Dec 12

Current report 8-K

Entered into a material agreement, Regulation FD disclosure

Dec 12

Current report 8-K

Regulation FD disclosure, Other events

Nov 20

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Nov 1

Current report 8-K

Financial results

Nov 1

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $11.07M ▲ 63.9% Net loss $27.04M Diluted EPS -$0.55

Sep 5

Current report 8-K

Director or officer change, or executive pay

Aug 8

Current report 8-K

Financial results

Aug 8

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $2.66M ▼ 80.7% Net loss $35.92M Diluted EPS -$0.73

Jun 20

Current report 8-K

Director or officer change, or executive pay, Shareholder vote results

May 30

Current report 8-K Events of May 29

Entered into a material agreement, Unregistered sale of equity

May 4

Current report 8-K

Financial results

May 4

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $3.76M ▼ 50.9% Net loss $34.78M Diluted EPS -$0.71

Apr 28

Proxy statement DEF 14A

Proxy statement

Apr 28

Annual report to holders ARS

Annual report to holders

Apr 28

Proxy statement DEFA14A

Proxy statement

Apr 18

Proxy statement PRE 14A

Proxy statement

Feb 23

Current report 8-K/A

Financial results

Feb 23

Current report 8-K

Financial results

Feb 23

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $31.1M ▼ 32.1% Net loss $128.18M Diluted EPS -$2.62

Feb 2

Current report 8-K Events of Jan 30

Director or officer change, or executive pay, Regulation FD disclosure

Jan 9

Current report 8-K

Regulation FD disclosure

Nov 3

Current report 8-K

Financial results

Nov 3

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $6.75M ▼ 20.5% Net loss $31.96M Diluted EPS -$0.65

Sep 22

Current report 8-K/A Events of Jun 22

Shareholder vote results

Aug 4

Current report 8-K

Financial results

Aug 4

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $13.83M ▲ 41.4% Net loss $27.41M Diluted EPS -$0.56

Aug 2

Current report 8-K Events of Jul 29

Director or officer change, or executive pay, Regulation FD disclosure

Jun 24

Current report 8-K Events of Jun 22

Shareholder vote results

Jun 17

Current report 8-K Events of Jun 15

Director or officer change, or executive pay

Jun 17

Proxy statement DEFA14A

Proxy statement

May 16

Current report 8-K

Other events

May 12

Proxy statement DEFA14A

Proxy statement

May 5

Current report 8-K

Financial results